1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is 15,45€ (+65,06%). The median is 15,45€ (+65,06%).
| Buy |
9 |
| Hold |
3 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Sep 2025 | |
|---|---|---|
| Revenue | 3.65m | - |
| Gross profit | 3.56m | - |
| Net profit | −985.24k | - |
| EBITDA | −877.85k | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 16.27m€ |
Number of shares | 1.72m |
52-week high/low | 9,44€ - 1,67€ |
| Dividends | No |
Beta | -0,14 |
P/E ratio | −6,96 |
PEG ratio | −0,04 |
P/B ratio | 8,37 |
P/S ratio | 1,70 |
Company profile
| Name | Evoke Pharma Aktie |
| CEO | Mark A. Kowieski |
| Employees | 3 |
Discover assets
Shareholders of Evoke Pharma Aktie also invest in the following assets
